Though the outlook for children with nephrosis has improved considerably since the advent of steroid therapy, there remains a small but significant number of patients who are either unresponsive to steroid therapy or have frequent relapses. Two recent long-term follow-up studies of children treated with steroids have shown that 9% and 25% died within 5 years (Cornfeld and Schwartz, 1966; Arneil and Lam, 1966) . On the premise that immune mechanisms may be involved in the genesis of the nephrotic syndrome, cytotoxic agents have been used to treat such patients since 1949 (Chasis, Goldring, and Baldwin) . Initially, only short courses were employed (Kelley and Panos, 1952; Baldwin et al., 1953) , and though immediate results were encouraging, attempts to induce long remissions were less successful. In the past decade there has been a new upsurge of interest in the use of such 'immunosuppressive agents' in the nephrotic syndrome (Coldbeck, 1963;  Received 31 December 1970. Grupe and Heymann, 1966; West, Hong, and Holland, 1966; Etteldorf et al., 1967; and Moncrieff et al., 1969) and better results have been achieved. However, most of the trials have been carried out in patients who have had steroid therapy, and no attempt has been made to assess the efficacy of this form of therapy when given from the start.
While recognizing the potential hazards of cytotoxic agents, it must be remembered that drug therapy of nephrosis in children is still entirely empirical, since the action of steroid and cytotoxic agents in this condition is unknown. Of the varieties of nephrosis where there is some evidence of an underlying immunological mechanism, such as nephrotic syndrome associated with quartan malaria (Soothill and Hendrickse, 1967; and Ward and Kibukamusoke, 1969) , infected ventriculoatrial shunts (Black, Challacombe, and Ockenden, 1965; Stickler et al., 1968) , and post-streptococcal glomerulonephritis (Michael et al., 1966) (Tsao, Chan, and Gibson, 1969) . Patients with severe proliferative changes in their renal biopsy were excluded because they are known to respond poorly to steroids (White, Cameron, and Trounce, 1966; and Tsao et al., 1969) . Patients with diffuse membranous glomerulonephritis were included if they also showed a selective type of proteinuria (Chan and Tsao, 1966 ). An initial observation period was instituted to exclude those about to undergo spontaneous remission, and to exclude tuberculosis and other forms of infection. Treatment was postponed whenever there was a febrile illness.
Nineteen patients were classified as 'minimal change', 8 as 'mild proliferative', and 4 as 'diffuse membranous glomerulonephritis'. They were assigned alternately to the two treatment groups according to their renal histology.
Cyclophosphamide was used at the dose of 3-5 mg/kg per day. The dose was adjusted so as to keep the white blood cell count just above 4,000/mm3. The course varied in individual patients from 6 months to 19 months. Prednisone was used at an initial dose of 2 mg/kg per day. This was maintained until the patient showed a significant reduction in proteinuria. The dose was then gradually reduced to half and maintained at this level until the blood chemistry had returned to normal or reached a steady state. It was then further reduced to 10 to 20 mg daily and maintained for 6 to 12 months at this level.
Results
As seen in the Table, (Fig. 1) Two of the patients on prednisone and one of the patients on cyclophosphamide still had proteinuria at the time of review. These apart, the mean duration of proteinuria was 3*9 months for the cyclophosphamide treated group and 2 4 months for the prednisone treated group. The difference becomes more impressive when their distributions are compared (Fig. 2) 
Discussion
The use of cyclophosphamide as the primary treatment of nephrosis in children enables its effects to be assessed more easily. The present study shows that, contrary to the conclusion of Grupe and Heymann (1966) , cyclophosphamide is effective when it is used alone without steroids. The short-term effects of cyclophosphamide and prednisone on children with nephrosis were very similar. The main advantage of cyclophosphamide therapy in the short term was the absence of relapse in the 15 patients so treated. In contrast, 6 of the 14 patients who responded initially to prednisone relapsed. The follow-up period is still not long enough to say whether the absence of relapse in the cyclophosphamide group is due to a longer period of remission, or to a reduction in the total incidence of relapse.
Two patients with minimal change in their renal histology who were steroid treated still have proteinuria 17 and 18 months after the start of treatment. This incidence of steroid resistance corresponds with our previous findings in a larger series (Tsao et al., 1969) and with our long-term follow-up studies. All except one of the patients treated with cyclophosphamide have attained remission. The exception is a patient with minimal change in his renal histology; he started treatment 12 months ago, and the proteinuria has become intermittent in the past 5 months. In the remaining patients the time taken to reach full remission varied from 2 weeks to 13 months. Treatment has been maintained throughout this period. The results emphasize the need to distinguish 'slow responders' from 'non-responders' and also suggest that therapeutic failure as commonly defined is only a relative term. Apart from the drug employed and the dosage and duration of treatment, it also depends on the time limit set for a response to occur. When the slow responders are excluded, the incidence of true resistance to cyclophosphamide is probably not high, but proper assessment can only be made when its use is more widely adopted.
Such definition of drug resistance is also critical in the interpretation of the results of any therapeutic trial. Thus, if 8 weeks is set as the time limit for a response to occur, 5 out of the 16 patients treated with prednisone and 10 out of the 15 patients treated with cyclophosphamide would be labelled as 'non-responders'. At 6 months from the start of treatment, the corresponding figures for the 'non-responders' would be 4 for the prednisonetreated group and 3 for the cyclophosphamidetreated group. The failure of azathioprine to produce any significant advantage over the placebo in the international study (Abramowicz et al., 1970) may be attributed partly to this phenomenon.
Our finding that patients treated primarily with cyclophosphamide relapse less than those treated with prednisone is similar to the results of other workers who used cyclophosphamide on steroidtreated frequent relapsers (West et al., 1966; Grupe and Heymann, 1966; Etteldorf et al., 1967, and Moncrieff et al., 1969) . There is, therefore, little advantage in using cyclophosphamide as the primary treatment of childhood nephrosis. However, if proteinuria is accepted as evidence of activity of the disease and if better results are to be obtained, it seems reasonable to suggest using cyclophosphamide in all patients who relapse after a steroid-induced remission. On the other hand, the potential hazards of cyclophosphamide must be recognized, particularly its effect on the immature gonads. Until its long-term risks are known, some may argue that cyclophosphamide should be reserved for patients who show signs of steroid toxicity.
The optimal duration of cyclophosphamide therapy is not established. West et al. (1966) have commented on the failure of earlier trials using cytotoxic agents, especially nitrogen mustard, to attain prolonged remission, and have related it to the inability to maintain therapy for an adequate period of time. Moncrieff et al. (1969) regarded 3 months as the minimum length of treatment for the frequent relapsers. In this study, the treatment has been continued for a minimum of 6 months. The advantage of a longer period of treatment is shown by the total absence of relapse over a comparable duration of follow-up.
Recently, Barratt and Soothill (1970) reported that it was possible to maintain the remission in steroid-sensitive relapsers with a short course of cyclophosphamide. Their patients were all in steroid-induced remission when cyclophosphamide was started. This may prove to be a better way of achieving maximum result with the minimum amount of cyclophosphamide and may prove more acceptable to the critics of cyclophosphamide therapy.
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